-
Mashup Score: 0
The ranibizumab biosimilar XSB-001 (Ximluci) demonstrated biosimilarity to the originator (Lucentis) in a phase 3 trial in neovascular age-related macular degeneration (nAMD).
Source: Center for BiosimilarsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Irish Pharmacists Lobby for Biosimilar Substitution - 4 year(s) ago
Pharmacists in Ireland say the country is losing out on hundreds of millions of dollars in savings owing to the absence of a biosimilar substitution policy.
Source: Center for BiosimilarsCategories: Latest Headlines, PayerTweet-
Irish Pharmacists Lobby for #Biosimilar Substitution https://t.co/HA7gtLWdMt
-
-
Mashup Score: 6ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis - 4 year(s) ago
The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).
Source: Center for BiosimilarsCategories: Latest Headlines, RheumatologyTweet-
Telemedicine will play an important role in the delivery of rheumatologic care during #COVID19 and beyond. The ACR has outlined 8 positions on the use of telemedicine to improve patient access and ensure quality care: https://t.co/6wKT9Cev5S (via @BiosimCenter)
-
-
Mashup Score: 1ASCO20 Virtual Biosimilars Roundup - 4 year(s) ago
Here is a collection of our coverage from ASCO20 Virtual, the annual meeting for the American Society of Clinical Oncology (ASCO).
Source: Center for BiosimilarsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
RT @BiosimCenter: Check out our #ASCO20 Virtual #Biosimilars Roundup @ASCO Watch here: https://t.co/q6B39J7Gim https://t.co/zx4RmfIBdM
-
-
Mashup Score: 0Higher Value Oncology Care is Needed, VA Doctor Says at ASCO - 4 year(s) ago
Devika Das, MBBS, reviews the evidence presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, and concludes that some deep reforms are needed in oncology care in terms of access to care.
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A tough take on what is needed to fix access to cancer care is the US : Higher Value #Oncology Care is Needed, VA Doctor Says at #ASCO20 @UABNews https://t.co/CXV7KCD14C
-
-
Mashup Score: 0Money and Control Influence Oncologists' Use of Biosimilars - 4 year(s) ago
Abstracts presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, revealed important data on physician prescribing of biosimilars and cost savings in the oncology space.
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Money + control influence #oncologists use of #biosimilars #ASCO20 https://t.co/MNnwwt7hto
-
-
Mashup Score: 0Biosimilar Pegfilgrasim Cuts OCM Expense, ASCO Study Finds - 4 year(s) ago
A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Biosimilar Pegfilgrasim Cuts #OCM Expense, @ASCO Study Finds #ASCO2020 https://t.co/QClKmHq3jU via @biosimcenter
-
-
Mashup Score: 0Part 2: Ali McBride Discusses Initiatives to Improve Physician Education on Biosimilars - 4 year(s) ago
Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses physician struggles tied to biosimilar utilization, the upcoming initiatives for the ACCC Biosimilars Center, and why physicians should be keeping an eye on…
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Part 2 of @BiosimCenter's interview with ACCC Past President Ali McBride (@sheik2411) is live now—check it out! https://t.co/9mhreRkSTx
-
-
Mashup Score: 0Part 1: NCCN Panel Discusses Patient Education on Biosimilars - 4 year(s) ago
Patient preferences play a large role in the effort to get biosimilars into the mainstream of therapeutics, and education is often a struggle, panelists said at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Annual Conference.
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #NCCN, a panel discusses how patient preferences affect #biosimilar uptake https://t.co/A82OvN7kZr
-
-
Mashup Score: 1Ali McBride Discusses ACCC Initiatives and Biosimilar Uptake - 4 year(s) ago
Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses the anticipated growth for the US biosimilar market and what the Association of Community Cancer Centers (ACCC) is doing to further uptake efforts.
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @BiosimCenter: Dr Ali McBride (@sheik2411) Discusses @ACCCBuzz Initiatives and #Biosimilar Uptake Watch here: https://t.co/ehHlHqwPoN h…
-
On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the June 2023 issue of the @AJMC_Journal® about how employers and their employees are utilizing direct-to-consumer #telehealth to reduce the cost of care. https://t.co/ChIG85Eqxn https://t.co/lellD8Snjk